Overview

Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder

Status:
Completed

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2, single center, single-dose, double-blind, placebo-controlled, 2-way crossover study to evaluate the safety and efficacy of SST-6007 in women with FSAD. A sufficient number of participants will be enrolled to yield 30 (approximately 15 pre-menopausal and 15 post-menopausal) participants to complete the SST-6007/Placebo Double-Blind, Dosing Phase of the study (Visit 2 and Visit 3).

Phase:

Phase 2

Details

Lead Sponsor:

Strategic Science & Technologies, LLC

Treatments:

Sildenafil Citrate